BioCentury
ARTICLE | Clinical News

Altimmune evaluating next steps for HBV vaccine

May 4, 2018 3:19 PM UTC

Altimmune Inc. (NASDAQ:ALT) said HepTcell (FP-02.2) given on days one, 29 and 57 as an add-on to entecavir or tenofovir was well tolerated but led to "inconclusive" T cell immunogenicity results in a Phase Ib trial in 60 patients with chronic HBV infection.

The company said it is evaluating next steps. Patients will be followed for six months and additional data from the double-blind, placebo-controlled, dose-escalation trial will be reported in 4Q18...

BCIQ Company Profiles

Altimmune Inc.